WAM
CRDF icon

Wolverine Asset Management’s Cardiff Oncology CRDF Stock Holding History

Wolverine Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1
Closed -$8K – 1825
2015
Q2 		$8K Buy
+1
New +$709 ﹤0.01% 1630

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wolverine Asset Management's CRDF Position: Q3 2015 in Review

Wolverine Asset Management sold out of Cardiff Oncology (CRDF) in Q3 2015, closing a stake of 78 shares — an estimated $57K sold.

Wolverine Asset Management first reported a position in CRDF in Q2 2015 and held it in 1 quarter. The position peaked at $57K in Q2 2015. 60 funds tracked by Wall St. Rank hold CRDF as of Q3 2015.

  • Wolverine Asset Management reported no remaining Cardiff Oncology position as of Q3 2015 after selling out during the quarter.
  • Wolverine Asset Management sold 78 Cardiff Oncology shares in Q3 2015, an estimated $57K.
  • Wolverine Asset Management first reported a position in Cardiff Oncology in Q2 2015 and held it in 1 quarter.
  • Wolverine Asset Management's Cardiff Oncology position peaked at $57K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2015.

Based on Wolverine Asset Management's 13F filing for Q3 2015, filed 17 Nov 2015.